Rescue of melanocortin 4 receptor (MC4R) nonsense mutations by aminoglycoside-mediated read-through

Obesity

Volumn 20, Issue 5, 2012, Pages 1074-1081

  Brumm, Harald ^a   Mühlhaus, Jessica ^a   Bolze, Florian ^b   Scherag, Susann ^c   Hinney, Anke ^c   Hebebrand, Johannes ^c   Wiegand, Susanna ^a   Klingenspor, Martin ^b   Grüters, Annette ^a   Krude, Heiko ^a   Biebermann, Heike ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CYCLIC AMP; LIGAND; MELANOCORTIN 4 RECEPTOR; MEMBRANE PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CELL STRAIN COS1; CELL SURFACE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE SEQUENCE; HOMEOSTASIS; HYPOTHALAMUS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NONSENSE MUTATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STOP CODON; WILD TYPE;

AMINOGLYCOSIDES; BLOOD-BRAIN BARRIER; CODON, NONSENSE; CODON, TERMINATOR; ENERGY METABOLISM; FEMALE; HUMANS; MALE; OBESITY; OXADIAZOLES; RECEPTOR, MELANOCORTIN, TYPE 4; SIGNAL TRANSDUCTION;

EID: 84860292980     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2011.202     Document Type: Article

References (43)

1. Farooqi IS, Keogh JM, Yeo GS et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003;348:1085-1095.
2. Tao YX. The melanocortin-4 receptor: Physiology, pharmacology, and pathophysiology. Endocr Rev 2010;31:506-543.
3. Farooqi IS, Jebb SA, Langmack G et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;341:879-884.
4. Hinney A, Hohmann S, Geller F et al. Melanocortin-4 receptor gene: Casecontrol study and transmission disequilibrium test confirm that functionally relevant mutations are compatible with a major gene effect for extreme obesity. J Clin Endocrinol Metab 2003;88:4258-4267.
5. Wangensteen T, Kolsgaard ML, Mattingsdal M et al. Mutations in the melanocortin 4 receptor (MC4R) gene in obese patients in Norway. Exp Clin Endocrinol Diabetes 2009;117:266-273.
6. Hinney A, Schmidt A, Nottebom K et al. Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. J Clin Endocrinol Metab 1999;84:1483-1486.
7. Hinney A, Bettecken T, Tarnow P et al. Prevalence, spectrum, and functional characterization of melanocortin-4 receptor gene mutations in a representative population-based sample and obese adults from Germany. J Clin Endocrinol Metab 2006;91:1761-1769.
8. Vaisse C, Clement K, Durand E et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000;106:253-262.
9. Stutzmann F, Tan K, Vatin V et al. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes 2008;57:2511-2518.
10. Larsen LH, Echwald SM, Sørensen TI et al. Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified among 750 men with juvenile-onset obesity. J Clin Endocrinol Metab 2005;90:219-224.
11. Tan K, Pogozheva ID, Yeo GS et al. Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4receptor. Endocrinology 2009;150:114-125.
12. Davies J, Gilbert W, Gorini L. Streptomycin, suppression, and the code. Proc Natl Acad Sci USA 1964;51:883-890.
13. Burke JF, Mogg AE. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res 1985;13:6265-6272.
14. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996;2:467-469.
15. Zingman LV, Park S, Olson TM, Alekseev AE, Terzic A. Aminoglycosideinduced translational read-through in disease: Overcoming nonsense mutations by pharmacogenetic therapy. Clin Pharmacol Ther 2007;81:99-103.
16. Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress disease-Associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med 2002;80:367-376.
17. Wilschanski M, Yahav Y, Yaacov Y et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003;349:1433-1441.
18. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104:375-381.
19. Sangkuhl K, Schulz A, Römpler H et al. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. Hum Mol Genet 2004;13:893-903.
20. Keeling KM, Brooks DA, Hopwood JJ et al. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 2001;10:291-299.
21. Du M, Jones JR, Lanier J et al. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J Mol Med 2002;80:595-604.
22. Welch EM, Barton ER, Zhuo J et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447:87-91.
23. Kerem E, Hirawat S, Armoni S et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial. Lancet 2008;372:719-727.
24. Biebermann H, Schöneberg T, Krude H et al. Mutations of the human thyrotropin receptor gene causing thyroid hypoplasia and persistent congenital hypothyroidism. J Clin Endocrinol Metab 1997;82:3471-3480.
25. Stäubert C, Tarnow P, Brumm H et al. Evolutionary aspects in evaluating mutations in the melanocortin 4 receptor. Endocrinology 2007;148:4642-4648.
26. Marti A, Corbalán MS, Forga L et al. A novel nonsense mutation in the melanocortin-4 receptor associated with obesity in a Spanish population. Int J Obes Relat Metab Disord 2003;27:385-388.
27. Reinehr T, Hebebrand J, Friedel S et al. Lifestyle intervention in obese children with variations in the melanocortin 4 receptor gene. Obesity (Silver Spring) 2009;17:382-389.
28. Farooqi IS, Wangensteen T, Collins S et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007;356:237-247.
29. Krude H, Biebermann H, Gruters A. Mutations in the human proopiomelanocortin gene. Ann N Y Acad Sci 2003;994:233-239.
30. Malik V, Rodino-Klapac LR, Viollet L et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 2010;67:771-780.
31. Manuvakhova M, Keeling K, Bedwell DM. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 2000;6:1044-1055.
32. Keeling KM, Lanier J, Du M et al. Leaky termination at premature stop codons antagonizes nonsense-mediated mRNA decay in S. cerevisiae. RNA 2004;10:691-703.
33. Salas-Marco J, Bedwell DM. Discrimination between defects in elongation fidelity and termination efficiency provides mechanistic insights into translational readthrough. J Mol Biol 2005;348:801-815.
34. Tao YX, Segaloff DL. Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects. J Clin Endocrinol Metab 2005;90:5632-5638.
35. Srinivasan S, Lubrano-Berthelier C, Govaerts C et al. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J Clin Invest 2004;114:1158-1164.
36. Yang YK, Fong TM, Dickinson CJ et al. Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry 2000;39:14900-14911.
37. Grosse R, Schöneberg T, Schultz G, Gudermann T. Inhibition of gonadotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. Mol Endocrinol 1997;11:1305-1318.
38. Heier CR, DiDonato CJ. Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. Hum Mol Genet 2009;18:1310-1322.
39. Linde L, Kerem B. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet 2008;24:552-563.
40. Auld DS, Thorne N, Maguire WF, Inglese J. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci USA 2009;106:3585-3590.
41. Wang B, Yang Z, Brisson BK et al. Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. J Appl Physiol 2010;109:901-905.
42. Olson TM, Alekseev AE, Liu XK et al. Kv1.5 channelopathy due to KCNA5loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 2006;15:2185-2191.
43. Howard MT, Anderson CB, Fass U et al. Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann Neurol 2004;55:422-426.